本文已被：浏览 344次 下载 300次
投稿时间：2025-05-16 网络发布日期：2025-10-20
投稿时间：2025-05-16 网络发布日期：2025-10-20
中文摘要: 目的 分析升血小板胶囊联合重组人血小板生成素（rhTPO）治疗肝病合并血小板减少患者的临床疗效和对肝功能的影响。方法纳入河北省人民医院2023年1月至2024年1月诊治的126例肝病合并血小板减少症患者，经随机抽签法分为两组，各63例，对照组给予rhTPO治疗，观察组在rhTPO治疗的基础上加用升血小板胶囊治疗，比较两组治疗效果及安全性。结果观察组的总有效率为96.83%，高于对照组的85.71%（χ2=4.881，P=0.027）；治疗后两组丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、总胆红素（TBil）水平均显著降低（P<0.05），且观察组低于对照组（P <0.01）；治疗后，两组患者血小板参数水平均升高，差异有统计学意义（P<0.05）；治疗后，与对照组相比，观察组凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）水平较低，凝血酶原活动度（PTA）水平较高（P<0.05），观察组炎症相关指标水平较低（P<0.05）；两组患者的免疫相关指标水平差异有统计学意义（P<0.05）；两组不良反应发生率对比差异无统计学意义（6.35% vs 3.17%，χ2=0.175，P=0.676）。结论肝病合并血小板减少患者经rhTPO与升血小板胶囊联合治疗后，血小板减少症状、免疫功能、炎症因子水平、凝血功能及肝功能均得到了改善，安全性尚可，临床效果理想。
Abstract:Objective To analyze the efficacy of Shengxuexiaoban capsules combined with recombinant human thrombopoietin（rhTPO）in the treatment of patients with liver disease and thrombocytopenia and its impact on liver function. Methods A total of 126 patients with liver disease and thrombocytopenia treated at Hebei General Hospital from January 2023 to January 2024 were enrolled and randomly divided into two groups（n=63，respectively）by lottery method. The control group received rhTPO alone，while the observation group received rhTPO plus Shengxuexiaoban capsules. Treatment efficacy and safety were compared between the two groups. Results The observation group demonstrated a significantly higher total effective rate（96.83%）compared to the control group（85.71%）（χ2=4.881，P=0.027）. After treatment，the two groups showed significantly greater improvements in alanine aminotransferase（ALT），aspartate aminotransferase（AST），and total bilirubin（TBil）levels compared to pre-treatment（P<0.05），and those in the observation group were superior to the control group（P <0.01）. Platelet parameters showed statistically significant intergroup differences（P<0.05）. Compared with the control group，the observation group had lower prothrombin time（PT）and activated partial thromboplastin time（APTT）levels，and higher prothrombin activity（PTA）levels，inflammatory markers（P<0.05）. Significant differences in inflammatory markers were observed between the two groups（P<0.05）. Importantly，no statistically significant difference was observed in incidence between groups（6.35% vs 3.17%，χ2=0.175，P=0.676）. Conclusion The rhTPO plus Shengxuexiaoban capsules regimen can effectively improve thrombocytopenia，immune/inflammatory status，coagulation function，and liver function in hepatopathic patients with thrombocytopenia，with good safety，optimal clinical outcomes.
keywords: Shengxuexiaoban capsules Recombinant human thrombopoietin Liver disease Thrombocytopenia Liver function Coagulation function Immune function Inflammatory factors
文章编号： 中图分类号：R554.6 文献标志码：A
基金项目:河北省卫生健康委员会医学科学研究课题（20230346）
附件
| Author Name | Affiliation |
| LIU Na*，LYU Chunlan，YAN Xiaofeng，REN Lu，WANG Yanan | Department of Gastroenterology,Hebei General Hospital,Shijiazhuang,Hebei 050000,China |
引用文本：
刘娜,吕春兰,阎晓风,等.升血小板胶囊联合重组人血小板生成素治疗肝病合并血小板减少的临床研究[J].中国临床研究,2025,38(10):1535-1539,1544.
刘娜,吕春兰,阎晓风,等.升血小板胶囊联合重组人血小板生成素治疗肝病合并血小板减少的临床研究[J].中国临床研究,2025,38(10):1535-1539,1544.